Research
FORUM TRANSCRIPT

JenaValve – Core Product Analysis & TAVR Market Disruption Opportunity

  • Private Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Former senior executive at JenaValve Technology Inc

Agenda

  • Major trends and developments in the heart valve replacement space, focusing on AR (aortic regurgitation) and AS (aortic stenosis)
  • Core value proposition and differentiation of JenaValve’s Trilogy device
  • Conclusion of ALIGN-AR clinical trial and preparation for US commercial product launch
  • Long-term growth strategy and untapped market opportunities

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo